Edition:
United States

MabVax Therapeutics Holdings Inc (MBVX.OQ)

MBVX.OQ on NASDAQ Stock Exchange Capital Market

2.14USD
23 Feb 2018
Change (% chg)

$0.05 (+2.39%)
Prev Close
$2.09
Open
$2.20
Day's High
$2.20
Day's Low
$1.96
Volume
40,912
Avg. Vol
19,156
52-wk High
$10.71
52-wk Low
$1.28

Latest Key Developments (Source: Significant Developments)

MabVax Therapeutics Says Reverse Stock Split Is Scheduled To Be Effective With Opening Of Trading On Feb 16
Thursday, 15 Feb 2018 07:30am EST 

Feb 15 (Reuters) - MabVax Therapeutics Holdings Inc ::MABVAX THERAPEUTICS SCHEDULES PREVIOUSLY ANNOUNCED 1-FOR-3 REVERSE STOCK SPLIT TO REGAIN COMPLIANCE WITH NASDAQ'S $1.00 MINIMUM BID PRICE MAINTENANCE REQUIREMENT.MABVAX THERAPEUTICS HOLDINGS INC - REVERSE STOCK SPLIT IS SCHEDULED TO BE EFFECTIVE WITH OPENING OF TRADING ON FEB 16, 2018.  Full Article

John Stetson Reports 4.99 Pct Stake In Mabvax Therapeutics Holdings
Monday, 12 Feb 2018 05:27pm EST 

Feb 12 (Reuters) - Mabvax Therapeutics Holdings Inc ::JOHN STETSON REPORTS 4.99 PERCENT STAKE IN MABVAX THERAPEUTICS HOLDINGS INC AS OF FEBRUARY 12 - SEC FILING.  Full Article

MabVax Therapeutics Announces Positive Interim Data From Trial of MVT-5873
Monday, 12 Feb 2018 07:01am EST 

Feb 12 (Reuters) - MabVax Therapeutics Holdings Inc ::MABVAX THERAPEUTICS ANNOUNCES POSITIVE INTERIM DATA FROM EXPANDED COHORT IN PHASE 1 TRIAL EVALUATING MVT-5873 IN COMBINATION WITH FIRST-LINE CHEMOTHERAPY IN PANCREATIC CANCER.MABVAX THERAPEUTICS HOLDINGS - ‍MVT-5873 AT A DOSE OF 0.125 MG/KG WHEN ADDED TO FIRST-LINE CHEMOTHERAPY WAS GENERALLY WELL TOLERATED BY ALL SUBJECTS​.MABVAX THERAPEUTICS HOLDINGS INC - ‍COMPANY PLANS TO ENROLL ADDITIONAL PATIENTS AT THIS DOSE TO FURTHER EXPLORE SAFETY AND POTENTIAL RESPONSE​.MABVAX THERAPEUTICS HOLDINGS INC - ‍AT DOSE TESTED, ALL SIX PATIENTS IN COHORT HAD MEANINGFUL REDUCTIONS IN TUMOR VOLUME BY RECIST​.  Full Article

Mabvax Therapeutics Holdings Provides Business Strategy Update
Tuesday, 16 Jan 2018 07:30am EST 

Jan 16 (Reuters) - Mabvax Therapeutics Holdings Inc ::MABVAX THERAPEUTICS HOLDINGS, INC. PROVIDES BUSINESS STRATEGY UPDATE.MABVAX THERAPEUTICS - ON TRACK TO EXECUTE CORPORATE AND CLINICAL MILESTONES IN FIRST HALF OF 2018.MABVAX - CURRENTLY IN "ADVANCED DISCUSSIONS" WITH A VARIETY OF INTERESTED PARTIES FOR POTENTIAL MULTIPLE DEAL PROPOSALS.  Full Article

MabVax Therapeutics Says Completed Patient Enrollment In Expanded Cohort Of Phase-1 Trial Testing MVT-5873
Wednesday, 20 Dec 2017 07:05am EST 

Dec 20 (Reuters) - Mabvax Therapeutics Holdings Inc ::MABVAX THERAPEUTICS ANNOUNCES COMPLETION OF ENROLLMENT AND INITIAL PATIENT DOSING IN AN EXPANDED COHORT OF THE PHASE 1 TRIAL EVALUATING MVT-5873 IN COMBINATION WITH FIRST-LINE CHEMOTHERAPY.MABVAX THERAPEUTICS SAYS PLANS TO ANNOUNCE INTERIM SAFETY AND RECIST DATA Q1 2018.  Full Article

MabVax Therapeutics Files For Resale Of 16.6 Mln Shares Of Co's Common Stock
Friday, 15 Dec 2017 06:15am EST 

Dec 15 (Reuters) - Mabvax Therapeutics Holdings Inc ::MABVAX THERAPEUTICS HOLDINGS INC FILES FOR RESALE OF 16.6 MILLION SHARES OF CO'S COMMON STOCK BY CERTAIN OF CO'S STOCKHOLDERS - SEC FILING.  Full Article

MabVax Completes Enrollment In Initial Cohort Of Its Cancer Drug
Wednesday, 13 Dec 2017 07:30am EST 

Dec 13 (Reuters) - MabVax Therapeutics Holdings Inc ::MABVAX THERAPEUTICS ANNOUNCES COMPLETION OF ENROLLMENT AND DOSING IN INITIAL COHORT OF MVT-1075 RADIOIMMUNOTHERAPY PHASE 1 TRIAL FOR THE TREATMENT OF PANCREATIC, COLON AND LUNG CANCERS.MABVAX THERAPEUTICS HOLDINGS INC - PLANS TO REPORT INTERIM RESULTS FROM STUDY EARLY IN Q1 OF 2018 AND CONTINUE DOSE ESCALATION PHASE OF PROGRAM.  Full Article

MabVax Therapeutics files for resale of 9.7 mln shares‍​
Wednesday, 25 Oct 2017 04:21pm EDT 

Oct 25 (Reuters) - MabVax Therapeutics Holdings Inc : :MabVax Therapeutics Holdings Inc - files for resale of 9.7 million shares of common stock of co by certain stockholders ‍​.  Full Article

MabVax Therapeutics files for resale of up to 6.97 mln shares of co's common stock‍​
Thursday, 19 Oct 2017 05:49pm EDT 

Oct 20 (Reuters) - MabVax Therapeutics Holdings Inc :MabVax Therapeutics Holdings Inc files for resale of up to 6.97 million shares of co's common stock‍​ by the selling stockholders - SEC filing‍​.  Full Article

Mabvax Therapeutics starts patient enrollment in phase 1 trial for cancer drug MVT-1075
Wednesday, 11 Oct 2017 08:00am EDT 

Oct 11 (Reuters) - Mabvax Therapeutics Holdings Inc :Mabvax Therapeutics initiates patient enrollment in a phase 1 trial for MVT-1075, a new radioimmunotherapy treatment for advanced pancreatic, colon and lung cancers.Mabvax Therapeutics Holdings Inc - ‍Plans to announce topline interim results before year end from study​.  Full Article

BRIEF-MabVax Therapeutics Says Reverse Stock Split Is Scheduled To Be Effective With Opening Of Trading On Feb 16

* MABVAX THERAPEUTICS SCHEDULES PREVIOUSLY ANNOUNCED 1-FOR-3 REVERSE STOCK SPLIT TO REGAIN COMPLIANCE WITH NASDAQ'S $1.00 MINIMUM BID PRICE MAINTENANCE REQUIREMENT